Pay in 4 interest-free payments of $6.67 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Learn more: May 2026 (state-dependent rollout): Medicaid access expands through the BALANCE Model
Tirzepatide is a dual GIP/GLP-1 receptor agonist, meaning it activates both glucose-dependent insulinotropic polypeptide receptors and GLP-1 receptors simultaneously
Endocr Pract 26(1):107139 Boye K, Ross M, Mody R, Konig M, Gelhorn H (2021) Patients preferences for once-daily oral versus once-weekly injectable diabetes medications: the REVISE study
At the 0.25 mg starting dose, even peak concentration is relatively modest
Supply Core, CDMOs Vital By Dean Rudge Stay ahead of every shift in generics and biosimilars
Scientists are also looking at how these peptides might help protect the skin from oxidative damage and support overall skin health
US$ 29.72
US$ 20.50
US$ 22.45
US$ 21.03
US$ 25.36
